Neumann Capital Management LLC lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 11.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 50,770 shares of the biopharmaceutical company’s stock after selling 6,704 shares during the quarter. Gilead Sciences accounts for 2.2% of Neumann Capital Management LLC’s holdings, making the stock its 14th largest holding. Neumann Capital Management LLC’s holdings in Gilead Sciences were worth $3,637,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of GILD. Welch Investments LLC purchased a new stake in Gilead Sciences in the third quarter valued at $108,000. Wealthcare Advisory Partners LLC purchased a new stake in Gilead Sciences in the third quarter valued at $133,000. Horan Capital Advisors LLC. purchased a new stake in Gilead Sciences in the third quarter valued at $144,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Gilead Sciences in the second quarter valued at $147,000. Finally, Hanson & Doremus Investment Management grew its stake in shares of Gilead Sciences by 806.5% in the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 1,613 shares in the last quarter. Institutional investors own 77.96% of the company’s stock.
A number of equities research analysts have recently weighed in on the company. Barclays reaffirmed an “overweight” rating and issued a $95.00 price objective (up from $90.00) on shares of Gilead Sciences in a research note on Tuesday, March 6th. BidaskClub cut Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, March 3rd. Zacks Investment Research raised Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Wednesday, February 28th. Royal Bank of Canada reaffirmed a “buy” rating and issued a $94.00 price objective on shares of Gilead Sciences in a research note on Friday, February 23rd. Finally, Leerink Swann reaffirmed a “market perform” rating and issued a $80.00 price objective (down from $83.00) on shares of Gilead Sciences in a research note on Thursday, February 22nd. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $88.61.
In other news, insider John C. Martin sold 50,000 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $73.62, for a total transaction of $3,681,000.00. Following the completion of the transaction, the insider now directly owns 3,046,766 shares of the company’s stock, valued at approximately $224,302,912.92. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Gayle E. Wilson sold 60,000 shares of the company’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $77.92, for a total value of $4,675,200.00. Following the transaction, the director now directly owns 182,258 shares of the company’s stock, valued at $14,201,543.36. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 430,268 shares of company stock valued at $34,074,395. Insiders own 1.30% of the company’s stock.
Gilead Sciences, Inc. (NASDAQ:GILD) opened at $79.74 on Friday. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $89.54. The company has a market capitalization of $104,155.56, a price-to-earnings ratio of 22.91, a P/E/G ratio of -1.83 and a beta of 1.24. The company has a current ratio of 2.74, a quick ratio of 2.67 and a debt-to-equity ratio of 1.53.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The firm had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $5.71 billion. During the same period in the previous year, the firm posted $2.70 EPS. Gilead Sciences’s revenue for the quarter was down 18.7% on a year-over-year basis. analysts anticipate that Gilead Sciences, Inc. will post 6.21 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be given a dividend of $0.57 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 annualized dividend and a dividend yield of 2.86%. The ex-dividend date is Thursday, March 15th. Gilead Sciences’s dividend payout ratio is currently 65.52%.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.